89Zr crefmirlimab berdoxam (CD8 ImmunoPET)
PET imaging of CD8+ T-cells in Oncology
Key Facts
About ImaginAb
ImaginAb is a private, clinical-stage biotechnology company developing targeted in vivo imaging agents based on antibody fragments ('minibodies'). Its lead asset, 89Zr crefmirlimab berdoxam (CD8 ImmunoPET), is in Phase 2 trials for imaging CD8+ T-cells in oncology and has an IND for autoimmune disease. The company operates a platform that generates targeted radiopharmaceuticals for PET and optical imaging, aiming to provide critical biomarkers for immunotherapy development and clinical management. ImaginAb's business model is primarily diagnostic, partnering with pharmaceutical companies and research institutions to accelerate immuno-oncology drug development and patient stratification.
View full company profileAbout ImaginAb
ImaginAb is a private, clinical-stage biotechnology company developing targeted in vivo imaging agents based on antibody fragments ('minibodies'). Its lead asset, 89Zr crefmirlimab berdoxam (CD8 ImmunoPET), is in Phase 2 trials for imaging CD8+ T-cells in oncology and has an IND for autoimmune disease. The company operates a platform that generates targeted radiopharmaceuticals for PET and optical imaging, aiming to provide critical biomarkers for immunotherapy development and clinical management. ImaginAb's business model is primarily diagnostic, partnering with pharmaceutical companies and research institutions to accelerate immuno-oncology drug development and patient stratification.
View full company profile